Cart is empty A research team led by Associate Professor Makoto Ikeya in the Department of Clinical Application at Kyoto University has developed a promising new therapeutic strategy for fibrodysplasia ossificans progressiva (FOP)—a rare and severely disabling genetic disorder—by combining low-dose rapamycin with mesenchymal stem/stromal cells (MSCs) derived from induced pluripotent stem (iPS) cells. The paper is published in the journal JBMR Plus.
Leave A Comment